GDTC — CytoMed Therapeutics Share News
0.000.00%
Last trade - 00:00- $10.97m
- $10.52m
- SG$0.32m
Brief: Cytomed Therapeutics Refutes "Misleading" Claims & Reaffirms Clinical Progress
Brief: Cytomed Therapeutics Completes Acquisition Of T Cell Technology From Uk To Treat Cancers In China And India
Brief: CytoMed Therapeutics To Start Dose Level 2 In Angelica Trial Q3 2025
Brief: Cytomed Therapeutics Ltd Files For Mixed Shelf Of Up To $50 Million
Brief: Cytomed Therapeutics Enters Business & Research Collaboration Agreement With Sunact
Brief: Update On Clinical Milestone - CytoMed Therapeutics
Brief: Osteopore Partners With Cytomed To Advance MSC-Powered Regeneration
Funding Support From NMRC Clinical Trial Grant
Brief: CytoMed Therapeutics Says Malaysian Patent Granted For Its Licensed Allogeneic CAR-Gamma Delta T Cell Technology
Brief: Cytomed Therapeutics Ltd Entered Into A Heads Of Agreement With Cytomed Therapeutics China Limited (Cytomed China)
Brief: Chinese Patent Granted For CytoMed Therapeutics' Licensed iPSC-Based Technology
Brief: Chinese Patent Granted For A*Star Spinoff, CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology
U.S. STOCKS ON THE MOVE-Microsoft, Genius Sports, Thermo Fisher
U.S. STOCKS ON THE MOVE-Keurig Dr Pepper, Applied Digital, Sweetgreen
U.S. STOCKS ON THE MOVE-First Horizon, Fidelity National, Caribou Biosciences
CytoMed Therapeutics rises on US patent for its technology
Brief: CytoMed Therapeutics Announce A Patent For Its Licensed Car-Gamma Delta T Cell Technology Has Been Granted In The US
Brief: Cytomed Therapeutics Limited Announces Collaboration With MD Anderson Cancer Center To Advance Allogeneic Off-The-Shelf Gamma Delta T Cells In Oncology
Brief: Glorious Finance Says Has 42.54% Stake In Cytomed Therapeutics Ltd As Of April 14 - SEC Filing